PURPOSE: To compare the risk of neoplastic progression by germline mutation status versus family history without a known germline mutation (familial risk) among individuals with an increased risk for pancreatic cancer who are undergoing surveillance. METHODS: Of 464 high-risk individuals in the Cancer of the Pancreas Screening program at Johns Hopkins Hospital who were undergoing pancreatic surveillance, 119 had a known deleterious germline mutation in a pancreatic cancer susceptibility gene; 345 met family history criteria for pancreatic surveillance but were not known to harbor a germline mutation. We used next-generation sequencing to identify previously unrecognized germline mutations among these 345 individuals. We compared the development of pancreatic cancer, high-grade dysplasia, or clinically worrisome features, adjusting for competing mortality, among all germline mutation carriers with the risk of progression in a cohort without a known germline mutation. RESULTS: Fifteen (4.3%) of 345 individuals classified as having familial risk had a previously unrecognized pancreatic cancer susceptibility gene mutation (nine that involved ATM, two BRCA2, one BRCA1, one PALB2, one TP53, and one CPA1). The cumulative incidence of pancreatic cancer, high-grade dysplasia, or worrisome features on pancreatic imaging was significantly higher in the germline mutation risk group (n = 134) than in the familial risk group (n = 330 [for pancreatic cancer, hazard ratio, 2.85; 95% CI, 1.0 to 8.18; P = .05]). CONCLUSION: The cumulative incidence of pancreatic cancer is significantly higher among individuals with an identifiable deleterious germline mutation in a pancreatic cancer susceptibility gene than it is among individuals with a strong family history but no identified mutation. Gene testing of individuals who meet criteria for pancreatic surveillance on the basis of their family history may better define those most at risk for neoplastic progression.
PURPOSE: To compare the risk of neoplastic progression by germline mutation status versus family history without a known germline mutation (familial risk) among individuals with an increased risk for pancreatic cancer who are undergoing surveillance. METHODS: Of 464 high-risk individuals in the Cancer of the Pancreas Screening program at Johns Hopkins Hospital who were undergoing pancreatic surveillance, 119 had a known deleterious germline mutation in a pancreatic cancer susceptibility gene; 345 met family history criteria for pancreatic surveillance but were not known to harbor a germline mutation. We used next-generation sequencing to identify previously unrecognized germline mutations among these 345 individuals. We compared the development of pancreatic cancer, high-grade dysplasia, or clinically worrisome features, adjusting for competing mortality, among all germline mutation carriers with the risk of progression in a cohort without a known germline mutation. RESULTS: Fifteen (4.3%) of 345 individuals classified as having familial risk had a previously unrecognized pancreatic cancer susceptibility gene mutation (nine that involved ATM, two BRCA2, one BRCA1, one PALB2, one TP53, and one CPA1). The cumulative incidence of pancreatic cancer, high-grade dysplasia, or worrisome features on pancreatic imaging was significantly higher in the germline mutation risk group (n = 134) than in the familial risk group (n = 330 [for pancreatic cancer, hazard ratio, 2.85; 95% CI, 1.0 to 8.18; P = .05]). CONCLUSION: The cumulative incidence of pancreatic cancer is significantly higher among individuals with an identifiable deleterious germline mutation in a pancreatic cancer susceptibility gene than it is among individuals with a strong family history but no identified mutation. Gene testing of individuals who meet criteria for pancreatic surveillance on the basis of their family history may better define those most at risk for neoplastic progression.
Authors: Marcia Irene Canto; Jose Alejandro Almario; Richard D Schulick; Charles J Yeo; Alison Klein; Amanda Blackford; Eun Ji Shin; Abanti Sanyal; Gayane Yenokyan; Anne Marie Lennon; Ihab R Kamel; Elliot K Fishman; Christopher Wolfgang; Matthew Weiss; Ralph H Hruban; Michael Goggins Journal: Gastroenterology Date: 2018-05-24 Impact factor: 22.682
Authors: Maeve A Lowery; Winston Wong; Emmet J Jordan; Jonathan W Lee; Yelena Kemel; Joseph Vijai; Diana Mandelker; Ahmet Zehir; Marinela Capanu; Erin Salo-Mullen; Angela G Arnold; Kenneth H Yu; Anna M Varghese; David P Kelsen; Robin Brenner; Erica Kaufmann; Vignesh Ravichandran; Semanti Mukherjee; Michael F Berger; David M Hyman; David S Klimstra; Ghassan K Abou-Alfa; Catherine Tjan; Christina Covington; Hannah Maynard; Peter J Allen; Gokce Askan; Steven D Leach; Christine A Iacobuzio-Donahue; Mark E Robson; Kenneth Offit; Zsofia K Stadler; Eileen M O'Reilly Journal: J Natl Cancer Inst Date: 2018-10-01 Impact factor: 13.506
Authors: Fay Kastrinos; Bhramar Mukherjee; Nabihah Tayob; Fei Wang; Jennifer Sparr; Victoria M Raymond; Prathap Bandipalliam; Elena M Stoffel; Stephen B Gruber; Sapna Syngal Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Hans Vasen; Isaura Ibrahim; Carmen Guillen Ponce; Emily P Slater; Elvira Matthäi; Alfredo Carrato; Julie Earl; Kristin Robbers; Anneke M van Mil; Thomas Potjer; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Wilma Bergman; Martin Wasser; Hans Morreau; Günter Klöppel; Christoph Schicker; Martin Steinkamp; Jens Figiel; Irene Esposito; Evelina Mocci; Enrique Vazquez-Sequeiros; Alfonso Sanjuanbenito; Maria Muñoz-Beltran; José Montans; Peter Langer; Volker Fendrich; Detlef K Bartsch Journal: J Clin Oncol Date: 2016-04-25 Impact factor: 44.544
Authors: Nicholas J Roberts; Yuchen Jiao; Jun Yu; Levy Kopelovich; Gloria M Petersen; Melissa L Bondy; Steven Gallinger; Ann G Schwartz; Sapna Syngal; Michele L Cote; Jennifer Axilbund; Richard Schulick; Syed Z Ali; James R Eshleman; Victor E Velculescu; Michael Goggins; Bert Vogelstein; Nickolas Papadopoulos; Ralph H Hruban; Kenneth W Kinzler; Alison P Klein Journal: Cancer Discov Date: 2011-12-29 Impact factor: 39.397
Authors: David B Zhen; Kari G Rabe; Steven Gallinger; Sapna Syngal; Ann G Schwartz; Michael G Goggins; Ralph H Hruban; Michele L Cote; Robert R McWilliams; Nicholas J Roberts; Lisa A Cannon-Albright; Donghui Li; Kelsey Moyes; Richard J Wenstrup; Anne-Renee Hartman; Daniela Seminara; Alison P Klein; Gloria M Petersen Journal: Genet Med Date: 2014-11-20 Impact factor: 8.822
Authors: Mark E Lowe; Dana K Andersen; Richard M Caprioli; Jyoti Choudhary; Zobeida Cruz-Monserrate; Anil K Dasyam; Christopher E Forsmark; Fred S Gorelick; Joe W Gray; Mark Haupt; Kimberly A Kelly; Kenneth P Olive; Sylvia K Plevritis; Noa Rappaport; Holger R Roth; Hanno Steen; S Joshua Swamidass; Temel Tirkes; Aliye Uc; Kirill Veselkov; David C Whitcomb; Aida Habtezion Journal: Pancreas Date: 2019 Nov/Dec Impact factor: 3.327
Authors: Makoto Kawamoto; Shiro Kohi; Toshiya Abe; Mohamad Dbouk; Anne Macgregor-Das; Chiho Koi; Ki-Byung Song; Michael Borges; Ryo Sugimine; Daniel Laheru; Ralph H Hruban; Nicholas Roberts; Alison P Klein; Michael Goggins Journal: Int J Cancer Date: 2021-12-06 Impact factor: 7.396
Authors: Amanda L Blackford; Marcia Irene Canto; Alison P Klein; Ralph H Hruban; Michael Goggins Journal: J Natl Cancer Inst Date: 2020-11-01 Impact factor: 13.506
Authors: Toshiya Abe; Chiho Koi; Shiro Kohi; Ki-Byung Song; Koji Tamura; Anne Macgregor-Das; Naoki Kitaoka; Miguel Chuidian; Madeline Ford; Mohamad Dbouk; Michael Borges; Jin He; Richard Burkhart; Christopher L Wolfgang; Alison P Klein; James R Eshleman; Ralph H Hruban; Marcia Irene Canto; Michael Goggins Journal: Clin Gastroenterol Hepatol Date: 2019-10-30 Impact factor: 11.382
Authors: Shiro Kohi; Anne Macgregor-Das; Mohamad Dbouk; Takeichi Yoshida; Miguel Chuidian; Toshiya Abe; Michael Borges; Anne Marie Lennon; Eun Ji Shin; Marcia Irene Canto; Michael Goggins Journal: Clin Gastroenterol Hepatol Date: 2020-11-05 Impact factor: 11.382
Authors: Elizabeth D Thompson; Nicholas J Roberts; Laura D Wood; James R Eshleman; Michael G Goggins; Scott E Kern; Alison P Klein; Ralph H Hruban Journal: Mod Pathol Date: 2020-07-23 Impact factor: 7.842
Authors: Michael Goggins; Kasper Alexander Overbeek; Randall Brand; Sapna Syngal; Marco Del Chiaro; Detlef K Bartsch; Claudio Bassi; Alfredo Carrato; James Farrell; Elliot K Fishman; Paul Fockens; Thomas M Gress; Jeanin E van Hooft; R H Hruban; Fay Kastrinos; Allison Klein; Anne Marie Lennon; Aimee Lucas; Walter Park; Anil Rustgi; Diane Simeone; Elena Stoffel; Hans F A Vasen; Djuna L Cahen; Marcia Irene Canto; Marco Bruno Journal: Gut Date: 2019-10-31 Impact factor: 23.059